Characterization of immunoglobulin binding by schistosomes

Area of Science:

• Parasitology
• Immunology
• Structural Biology

Background:

• Schistosomes are known to acquire host antibodies (immunoglobulins, Ig) for immune evasion.
• This antibody cloak may mask the parasite's foreign identity or disrupt immune functions.
• Paramyosin, a schistosome protein, has been previously identified as a potential Fc-receptor binding human IgG.

Purpose of the Study:

• To characterize the interaction between the Fc region of immunoglobulins and schistosome paramyosin.
• To investigate the binding specificities of paramyosin for different immunoglobulin classes.
• To elucidate the molecular mechanisms underlying the interaction between paramyosin and IgG.

Main Methods:

• Recombinant paramyosin was used to study binding interactions with various immunoglobulin classes.
• Experiments were conducted to assess the association of bound Ig with other parasite proteins.
• Functional assays were performed to investigate the role of paramyosin-Ig binding in Fc-receptor mediated functions, such as NADPH respiratory bursts.
• Inhibition assays using Protein G were employed to probe the binding site on IgG.

Main Results:

• Paramyosin demonstrated binding to specific immunoglobulin (Ig) classes, notably murine IgG2b and IgG3.
• Bound immunoglobulins were observed to associate with other parasite proteins.
• Paramyosin-IgG binding did not inhibit FcgammaR-mediated NADPH respiratory bursts, suggesting a non-canonical binding interaction.
• Protein G, which binds a known Fc-receptor site, could not block paramyosin-IgG binding.

Conclusions:

• Schistosome paramyosin binds specific host immunoglobulin classes, particularly murine IgG2b and IgG3.
• The binding interaction is distinct from known Fc-receptor binding sites on IgG.
• A low-affinity hydrogen bonding mechanism between a hydrophobic patch on IgG's Cgamma3 domain and negatively charged residues in paramyosin is postulated.
• This interaction likely contributes to the parasite's immune evasion strategies.